Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Mumbai Teen Anshika Aashish Mangal becomes Fastest Indian Female to Complete Commercial Pilot Training in USA Lifestyle
  • Empowering Future Leaders: BRICS CCI Young Leaders Summit 2.0 – Leadership Dialogue National
  • SachWorld Sports and Live Wire Sporting Ventures Strengthen Franchise Cricket and Talent Development in Uttarakhand Sports
  • Scientific Exploration of Spirituality: The Maha Kumbh Mela Special Lifestyle
  • Hyderabad’s AKS IAS Academy Achieves 63+ Selections in UPSC 2024, Becoming the Top Institute from Telangana Education
  • Cancer Patients Aid Association Announce ‘Pink & Teal’ in association with Social Aviator — A Women-Only Fundraising Gala Celebrating Womanhood on 6 March 2026 Lifestyle
  • A Legendary Offering: Ustad Amjad Ali Khan Unveils Never-Before-Heard Ragas in Inimitable Entertainment
  • Rajsha Pharmaceuticals Launches a New Range of Innovative Ayurvedic Products Business

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • “Navigator Emerging Market Fund’’ is all set to become a market leader by Building and Preserving Wealth Business
  • SIBM Pune and Swansea University to launch an online seminar series on metaverse Press Release
  • Radhika Ayurveda: Guiding people on the path to holistic health and wellness Health
  • Top Innovative Company Awards 2024 by the Global C-Suite Community Platform Press Release
  • Dr. Rekha Chaudhari’s book “India’s Ancient Legacy of Wellness“ launched in presence of Honorable Governor Shri Bhagat Singh Koshyari Ji and Smita Thackeray Ji Press Release
  • CR Patil and Rashmi Saboo promote the financial empowerment of 100 girls with Sukanya Samriddhi Yojana accounts Press Release

Recent Posts

  • World Record Holder Vineet Singh Hukmani Releases First Global Mahjong Anthem From India.
  • Delhi Witnesses Young Aavya M Bhutoria’s Kathak Debut at Aarohan 2026
  • Birth Centenary Celebrations to Convey the Message of Nation-Building Through Coordination Between Religious and Political Institutions
  • IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa
  • Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Surat to host ‘Maha Kumbh’ of Real Estate: HALO Property Expo 2026 to Open on April 24 Business
  • Attaining ascetic life is only possible through great fortune: Acharya Shri Mahashraman Lifestyle
  • Resonance Global Celebrates Students exceptional Achievements in International Tests, SAT and IELTS Education
  • Brand Endorsements Bring Fortune and Fame Says Actor Preet Bal Entertainment
  • Karnavati Club hosts Gujarat’s largest bumper housie with Rs. 1.25 cr in prizes Lifestyle
  • Emerald Finance Limited Strengthens Earned Wage Access Platform with Multiple Employer Partnerships Business
  • BNI Ahmedabad to host Symposium 2026, bring together 10,000+ business leaders Business
  • CapSavvy’s unique CRM Software successfully empowers 100 Users across various SMEs Business

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme